GRACE :: Global Resource for Advancing Cancer Education
Share
  • Recent GRACE News & Posts

    • Immunotherapy Combinations [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.
    • Immunotherapy as First-Line Treatment [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
    • Lung Cancer Screening - Process and Potential Benefits [GRACE :: Lung Cancer]
      Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.
    • Coming Soon [GRACE :: Blood Cancers]
      Blood Cancers posts are coming soon.
    • Bronchoscopy and EBUS [GRACE :: Lung Cancer]
      Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.
    • Maintenance Therapy for Advanced NSCLC [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
    • Rociletinib/Osimertinib for EGFR T790M-negative NSCLC [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
    • Are There Clinically Significant Distinctions Between PD-1 and PD-L1? [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
    • Histology-Specific Recommendations - Large-Cell Neuroendocrine [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
    • Histology-Specific Regimens - Squamous [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
    • Histology-Specific Regimens - Adenocarcinoma [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
    • What is the Role of Bevacizumab in Stage IV NSCLC? [GRACE :: Lung Cancer]
      Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

Ask Us, Q&A

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Recent GRACE Forum Topics

Recent GRACE Forum Replies

Other Resources

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243